mRNA Cap 2'-O-Methyltransferase, GMP-Grade DMF #038029

Product Description: mRNA Cap 2'-O-Methyltransferase, utilizing S-adenosylmethionine (SAM) as a methyl group donor, adds a methyl group at the 2'-O position of the first nucleotide adjacent to the Cap0 structure at the 5' end of RNA to obtain m7Gppp5'mN Cap1 structure. Cap1 structure is a signature of self RNA.and has been shown to modulate binding of innate immune sensors. For instance, the binding affinity of IFIT-1 for Cap1 is much weaker than for 5' triphosphate or Cap0 structure, Cap1 structure abrogates RIG-1 signaling and prevents detection by MDA5. NOTE: Vaccinia Capping Enzyme KT-GMP-VCS-VE101) is required to generate Cap0 structure. This product has been filed with the FDA Drug Master Files (DMF) and is assigned DMF #038029. Concentration: 50U/µL. Unit Definition: One unit is defined as the amount of enzyme required to methylate 10 pmoles of 80 nt long capped RNA transcript in 1 hour at 37°C. Source: Expressed in an E.coli strain with the gene of mRNA Cap 2'-O-Methyltransferase. Quality Standards: Activity (Capping modification and efficiency measurement): > 67.7 kU/mL, Purity (SEC-HPLC): > 95%, Residual DNase: Negative, Residual RNase: Negative, Residual Protease: Negative, Endotoxin: <= 5 EU/mL, Residual Host Cell DNA: <= 100 pg/mg, Residual Host Protein: <= 20 ng/mg, Residual Heavy Metal: <= 10 ppm, Residual Nickel Salt: <= 10 ppm, Bioburden: <= 1 CFU/10mL.